Age: 30.0
Sex: F
Vaccine: ANTH, FLU(H1N1), SMALL, YF, ANTH, FLU(H1N1), SMALL, YF
Symptoms: Activities of daily living impaired, Alanine aminotransferase normal, Anti-cyclic citrullinated peptide antibody, Antibody test normal, Antinuclear antibody negative
Clinical narrative: This case was received on 29 March 2012 via a third party query tool search on VAERS database, under reference number 447618. A 30-year-old female patient received the following vaccinations on 24 November 2009: ACAM2000 (SP Biologics Co. lot number not reported), YF VAX (Sanofi Pasteur, Inc., lot number UF317AA), EMERGENT (lot number FAV219) and H1N1 (Novartis, lot number I02040P1A). Within four to eight hours, the patient felt she had come down with the flu due to the symptoms of body aches, malaise and fatigue. The patient stayed in bed the next day because she continued to feel poorly. The physician told the patient it would resolve in a month's time and to treat symptomatically. Into December, the patient noticed an increase of symptoms including muscle and joint aches, increasing fatigue, generalized weakness, disruption to sleep pattern, mental fog including forgetfulness and poor concentration, and headache (HA) on right side of head. The patient continued to have symptoms when she left for her job in January of 2010, feeling like she had a really bad case of the flu and had to force herself to go to work, couldn't sleep at night, hard time working due to poor concentration and forgetfulness, difficulty walking due to the muscle and joint pain and weakness. The patient received dose two of AVA on 30 January 2010 and felt as if she had a worsening of symptoms especially increasing joint and muscle pain, fatigue and more disruption to her sleep cycle. The patient was sent back from her job in February of 2010 because she was unable to function at her job. The patient was told that her symptoms were due to depression. In June of 2010, the patient saw a rheumatologist and was diagnosed with fibromyalgia. The patient was also seen in neurology for the headache, which got progressively worse. The patient's laboratory testing on 14 June 2010 included: CCP 2; WBC 6.29; RBC 4.69; HGB 12.4; HCT 37.8; PLT 291; Albumin 4.2; Alk phos 55; SGPT 11; SGOT 13; BUN 12; Ca 9.3; Chloride 105; Total protein 7.4; Creat. 0.9; Glucose 88; K+ 3.9; Na 138; Total bili 0.3; ESR 23; CRP 1.14; RF <5.00; ANA neg; TSH 4.0; and on 14 December 2010: Thyrotropin Sensitive 2.36 mcIU/mL; Cholesterol/HDL Cholesterol 3.7; WBC 4.24 (L) x 10 (3)/mcL; RBC 4.72 x 10(6); Hematocrit 38.6%; MCV 81.7 fL; MCHC 33.4 g/dL; RDW CV 12.3%; Platelets 283 x10 (3)/mcL; MPV 6.1 (L) fL; Lymphocytes 32.4%; Monocytes 6.7%; Neutrophils 58.3%; Eosinophils 1.6%; Basophils 1.0%; Lymphocytes 1.4 x 10(3); Monocytes 0.3 x10(3); Neutrophils 2.5 x10(3). The patient also had a normal antibody test, normal bone scan, increased complement factor C3, decreased complement factor, complement factor C4 test, normal nerve conduction studies, abnormal nuclear magnetic resonance imaging of the brain, normal scan, whole body scan, decreased eosinophil count, normal aspartate aminotransferase, decreased basophil count, and a normal x-ray. Other medications and prior vaccinations were not reported. Current illnesses and history were reported as none. The patient's outcome was disabled and not recovered. Documents held by sender: None.